Temozolomide-associated organizing pneumonitis.
Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.
Maldonado
Fabien
F
Division of Pulmonary and Critical Care Medicine, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. maldonado.fabien@mayo.edu
Limper
Andrew H
AH
Lim
Kaiser G
KG
Aubrey
Marie-Christine
MC
D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D008297:Male; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide